Castle Biosciences (CSTL) CCO Juvenal Tobin Sells Shares

What Happened

• Juvenal Tobin, Chief Commercial Officer of Castle Biosciences (CSTL), reported multiple open‑market sales totaling 19,040 shares for aggregate proceeds of approximately $556,174. The trades occurred on July 31, 2026 and August 3, 2026 and are reported as dispositions (sales), not purchases.

Key Details

• Transaction breakdown:
  • 2026-07-31: 8,149 shares sold at a weighted-average price of $28.84 — $235,033 (executed in multiple trades; price range reported 28.150–29.140).
  • 2026-07-31: 7,270 shares sold at $29.58 — $215,039 (executed in multiple trades; price range reported 29.150–30.130).
  • 2026-07-31: 1,891 shares sold at $30.26 — $57,229 (executed in multiple trades; price range reported 30.150–30.645).
  • 2026-08-03: 1,730 shares sold at $28.25 — $48,873 (executed in multiple trades; price range reported 28.030–28.630).
• At least one of the July 31 transactions was executed pursuant to a Rule 10b5‑1 trading plan adopted by Tobin on December 10, 2025.
• Shares owned after the transactions are not specified in the information you provided.
• Filing: Form 4 was filed with accession date 2026-08-04. No late‑filing flag was indicated in the provided data.

Context

• These were sales (dispositions). Sales can be routine (e.g., diversification, tax planning) and the presence of a 10b5‑1 plan suggests at least some trades were pre‑arranged rather than timed to company news. This filing is informational; it does not by itself indicate Tobin’s view of Castle Biosciences’ prospects.